资讯

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...
The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April. After sweeping cuts ...
US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...
AGC Biologics has collaborated with Quell Therapeutics to advance the development of several T-regulatory (Treg) cell therapy ...
Pathos AI has raised $365m in a Series D funding round to widen its AI-enabled platform to advance the development of ...
The executive order instructs the FDA to expedite the approval process for domestic pharmaceutical manufacturing facilities.
The FDA approved 19 biosimilars in 2024, a sharp jump from the five greenlit by the agency in 2023. 2024 saw the highest ...
The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and ...
Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.
AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...